publication date: Oct. 30, 2020
Issue 41 - Oct. 30, 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Conversation with The Cancer Letter

    Owkin’s AI model provides proof of concept that machine learning can predict gene expression across cancer types

    Will an oncologist of the not-so-distant future be able to pull up an image of a tumor biopsy slide on a screen and—without having to order a biomarker test—see the molecular characteristics of the cancer?

  • Racism is a malignancy: Ibram X. Kendi reflects on his cancer experience

    After receiving a stage 4 colon cancer diagnosis, author Ibram X. Kendi sought consultation at two hospitals located a mile apart.

  • In Brief

    • AACR 2021 annual meeting will be virtual
    • C. Ola Landgren named the inaugural leader of experimental therapeutics at Sylvester
    • Ingo Mellinghoff named chair of MSK Department of Neurology
    • Beth Gaffney named VP of U.S. and global business development at NCCN
    • Reagan-Udall receives $250,000 from Rockefeller Foundation for COVID-19 Diagnostics Evidence Accelerator
    • Global Cancer Institute extends programs for underserved cancer patients to Bangladesh
  • TCCL Logo

  • Trials & Tribulations

    Toward a new kind of lung cancer awareness: Addressing financial toxicity

    November is Lung Cancer Awareness Month, a time to turn our attention to an issue that already warrants our focus year-round.

  • Clinical Roundup

    • USPSTF draft guideline: Colorectal cancer screening should start at 45
    • Study: Racial disparities in treatment NSCLC persist despite gains
    • Winship study shows increased DFS rates for men with prostate cancer
    • New York Proton Center joins RadComp clinical trial evaluating proton v. photon therapy in non-metastatic breast cancer
  • Drugs & Targets

    • FoundationOne CDx test receives FDA approval as companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi
    • FDA approves cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in NSCLC
    • CPI-613 receives FDA orphan drug designation for soft tissue sarcoma
    • Exact Sciences to acquire Thrive Earlier Detection
    • EQRx licenses two immune checkpoint inhibitors from CStone Pharmaceuticals.
    • StrataNGS genomic profiling receives Medicare coverage in patients with advanced solid tumors

Copyright (c) 2020 The Cancer Letter Inc.